SCHEMBL1638485

SCHEMBL1638485

O=C(NN=Cc1c(O)ccc2ccccc12)c1ccccc1NS(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.66
RRM1 P23921 7/20 0.63
MEN1 O00255 6/20 0.59
KMT2A Q03164 6/20 0.59
ALDH1A1 P00352 2/20 0.59
IDO1 P14902 2/20 0.57
NPC1 O15118 2/20 0.53
RAB9A P51151 1/20 0.53
PAX8 Q06710 1/20 0.52
MAPT P10636 3/20 0.51
HTT P42858 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
HKDC1 Q2TB90 1/20 0.50
KDM4E B2RXH2 1/20 0.49
LMNA P02545 1/20 0.49
HSP90AA1 P07900 1/20 0.49
GAA P10253 1/20 0.49
HPGD P15428 1/20 0.49
ALOX12 P18054 1/20 0.49
PTBP1 P26599 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12766783 1.00 PPARG (0.66) PPARGRRM1MEN1KMT2AALDH1A1
SCHEMBL1638311 0.79 NTRK1 (0.60) RRM1MEN1KMT2AALDH1A1NPC1
SCHEMBL1638314 0.79 NTRK1 (0.60) RRM1MEN1KMT2AALDH1A1NPC1
SCHEMBL29366011 0.78 RRM1 (1.00) PPARGRRM1MEN1KMT2AIDO1
SCHEMBL1637575 0.78 RRM1 (1.00) PPARGRRM1MEN1KMT2AIDO1
SCHEMBL4454258 0.78 RRM1 (1.00) PPARGRRM1MEN1KMT2AIDO1
SCHEMBL1637574 0.78 RRM1 (1.00) PPARGRRM1MEN1KMT2AIDO1
SCHEMBL1638624 0.77 MAPT (0.60) PPARGMEN1KMT2AALDH1A1NPC1
SCHEMBL1638623 0.77 MAPT (0.60) PPARGMEN1KMT2AALDH1A1NPC1
SCHEMBL18963239 0.75 RRM1 (1.00) PPARGRRM1MEN1KMT2AIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS APP, APBA1, BACE1 PPARG 2743/4885RRM1 3099/4885MEN1 2974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.